Trial intelligence / Profile preview

Ibrutinib vs chlorambucil in elderly untreated CLL/SLL

CTR20130303Phase 3Completed

Sponsor
Janssen Pharmaceutical
Start
Jun 2015
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Janssen Pharmaceutical. Started Jun 2015; status: completed.

02

Drugs

ibrutinib
03

Conditions

chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Beyond the preview

Go deeper on CTR20130303.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20130303.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call